Galderma signs USD 1.5 billion ZO deal. Galderma stock costs EUR 184.08

Published on 10/15/2026 at 10:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ZO Skin Health brings 40 products and 16,500 accounts in 40 countries. Galderma stock costs EUR 184.08 on October 15, 2026, with CHF 40.0 billion value.

Portfolio expansion and market context

Galderma agreed to acquire 100% of ZO Skin Health on October 14, 2026.
ZO Skin Health operates with 16,500 accounts across more than 40 countries.
Galderma stock traded at EUR 184.08 at 10:08 a.m. CEST at Lang & Schwarz on October 15, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma (CH1335392721) signed an agreement on October 14, 2026, to acquire 100% of ZO Skin Health for an enterprise value of USD 1.5 billion, according to Galderma. The stock was trading at EUR 184.08 at Lang & Schwarz on October 15, 2026 at 10:08 a.m. CEST.

Why the ZO deal matters

The transaction expands Galderma's physician-dispensed skincare business and adds ZO Skin Health to a portfolio that already includes Cetaphil and Alastin. The all-cash purchase will be funded through existing cash reserves and bank financing, and the closing is expected in the fourth quarter of 2026 or early 2027, subject to regulatory approvals, according to Business Wire.

ZO Skin Health brings more than 40 products and recorded net sales of USD 330 million in the 12 months through June 2026. Its products are sold through more than 16,500 physician, medical spa and online accounts across more than 40 countries. Galderma expects the acquisition to be neutral for core earnings per share in the first full year after closing, while its core EBITDA margin is expected to face slight dilution in 2027, according to Galderma.

What comes next for the portfolio

The chronology shows three dated developments: Galderma shareholders approved a gross dividend of CHF 0.35 per dividend-bearing share on April 22, 2026; Galderma presented three-year Nemluvio data at the Fall Clinical conference from October 8 to October 11, 2026; and it announced the ZO Skin Health acquisition on October 14, 2026. The next stated timing is the transaction closing in the fourth quarter of 2026 or early 2027, as reported by Galderma.

Stock price and investor context

Galderma's market capitalization was CHF 40.0 billion on October 15, 2026, based on the latest structured market snapshot. Its primary listing is SIX under the ticker GALD. The acquisition gives investors a concrete integration milestone, while the expected 2027 margin dilution places execution alongside portfolio expansion.

Trading level in Zurich

Galderma stock was trading at EUR 184.08 at Lang & Schwarz on October 15, 2026 at 10:08 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.